Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Signs Global License for Ingenuity's IPA Software

NEW YORK (GenomeWeb News) - Ingenuity Systems today said that AstraZeneca has signed a global licensing agreement for its IPA pathway analysis platform.
Adriano Henney, director of discovery enabling capabilities and sciences at AstraZeneca, said in a statement that the company opted for IPA after testing several platforms across seven AstraZeneca sites in three countries for the past year.
According to Ingenuity, IPA supports data analysis for all high-throughput analysis platforms and can be used for toxicology, pharmacogenomics, and biomarker validation.
Financial terms were not disclosed. 

Filed under